Reimbursed Care Access in Wallis and Futuna

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Esketamine (Spravato) holds a centralized marketing authorisation across the EU and was authorised by the European Medicines Agency (marketing authorisation valid throughout the EU on 18 December 2019). It is indicated as an add‑on intranasal treatment for adults with treatment‑resistant major depressive disorder (used in combination with an oral antidepressant) and is administered under restricted conditions (clinic/hospital setting, supervised administration). #

In France the French health technology assessment and medicines regulation pathway requires hospital restriction and specific prescription conditions: SPRAVATO is reserved to hospital use, subject to regulations applying to narcotic medicines, and the French Commission de la Transparence issued an opinion which supported restricted reimbursement (noting a limited SMR). Prescription is typically restricted to psychiatrists and administration is supervised in healthcare facilities; funding/reimbursement in French territories follows the French reimbursement procedures and hospital funding mechanisms, which determines whether and how hospital providers recover the high acquisition cost. #

Because Wallis and Futuna are an overseas collectivity of France, French medicines authorisations and hospital prescription/regulatory restrictions apply in principle; availability in local hospitals depends on the local health service capacity and hospital procurement/financing arrangements. (Wallis and Futuna are administered as French territories under French law for matters including health administration). #

Practical reimbursement and access: in metropolitan France SPRAVATO has been subject to hospital‑only use and specific reimbursement considerations (SMR assessed by the Commission de la Transparence) and is expensive for institutions — local uptake in Wallis and Futuna will depend on hospital capacity and funding flows under the French system. #

Ketamine (the racemic formulation and products used as anaesthetic) is a legally authorised medicine for anaesthesia and analgesia in France and is used off‑label in some psychiatric settings (intravenous low‑dose protocols) for treatment‑resistant depression under clinician discretion and within hospital settings; this use is generally off‑label and not covered by a dedicated national reimbursement pathway outside standard hospital funding or clinical trial budgets. Clinical and professional guidance in France discusses protocols and monitoring for IV ketamine in psychiatry; national drug safety agencies and professional societies monitor and publish recommendations. #

In practice in French territories (including Wallis and Futuna) ketamine as an anaesthetic is available through hospital services; off‑label psychiatric use requires specialist prescription and is generally funded through hospital budgets or private arrangements rather than a standard outpatient reimbursement. Professional societies (e.g., French anesthesiology/psychiatry groups) have issued recommendations on prescribing and monitoring. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Note: DMT is listed internationally under restrictive scheduling and is controlled in France as a stupéfiant. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no routine authorised medical pathway for ibogaine in France. #

Because its primary active constituent (DMT) is a controlled substance, ayahuasca preparations containing DMT fall under the same restrictive controls and are classified as illegal except within authorised research. Currently no authorised medical/therapeutic access exists outside approved clinical trials. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (Note: vegetal exceptions like certain indigenous peyote protections are not generally applicable in French law; mescaline as a molecule is controlled). #

Currently classified as a strictly controlled substance (analogue/phenethylamine class) under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #